Saturday, March 18, 2017 12:47:41 PM
I think we can agree that the only NDA submission to the FDA so far was many years ago -- so any new data supporting a 7 day shelf life has not yet been submitted.
Bryce
I don't think there is formulation difference between Canada's version and Europe's version. I remember hearing this in one of the CC's years ago and just found information that relates to your questions.
One thing though, the delivery device has been upgraded / changed. So your end question might still apply to that aspect. If not, Vitaros would possibly be approved by the FDA with a failed delivery device.
Based on Richard Pascoe's answer to how Health Canada is more stringent versus the European regulatory agencies when it comes to product specification and how it relates to shelf life. I think the question would be: How does the FDA compare to Health Canada in this respect? This in respect to shelf life.
I am posting the CC where this information can be reviewed.
Jason N. Butler - JMP Securities LLC, Research Division
Okay, great. And then just on Abbott and Vitaros in Canada, you said there was something specific about the formulation in Canada Abbott were working on. Can you maybe just give us a little bit of color about that? Or, if not, at least give us some color why that is not applicable in Europe?
Richard W. Pascoe
Certainly. First of all, there's not a difference in formulation, necessarily. The -- each country's regulatory authorities when they approve a product such as ours will set certain specifications and limits on manufacturing. And just to sort of oversimplify it, in this case, when the specifications for active ingredient or inactive ingredients are set on a very narrow range or the limits, in particular, the lower limits are set at a lower level that is potential higher than they might be somewhere in some other country, that relates directly to the amount of shelf life one can achieve with the product.
So in Canada, their specifications are much more stringent than they are in other territories, such as Europe. And I think just to maybe put it into perspective, when you compare the specifications for the Canadian product to the specifications for the European product, you are able to achieve, roughly, a doubling in shelf life from what is available in Canada to what will be available in Europe. So this is a specification issue that Abbott is working with or working through. They're working with their contract manufacturing partner, and they continue to be focused on getting the product into the market as soon as possible. But they are also very cognizant and aware of the fact that they need to launch the product with confidence. And that's what they're working through right now.
http://seekingalpha.com/article/1424051-apricus-biosciences-management-discusses-q1-2013-results-earnings-call-transcript?part=single
Recent SEEL News
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 03/06/2024 10:32:04 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 09:50:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:39:18 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/14/2024 09:50:49 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/06/2024 10:26:45 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/02/2024 11:04:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 09:01:23 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/30/2024 11:05:53 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:05:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 02:47:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 02:47:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 09:16:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:46:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:45:51 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:45:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:45:13 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/02/2024 01:10:24 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/22/2023 09:01:19 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/22/2023 01:10:14 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/20/2023 09:59:16 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/20/2023 09:54:15 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/18/2023 09:54:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/15/2023 09:06:26 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/04/2023 09:05:27 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM